How do NOACs Change Stroke Prevention in AF?

Professor John Camm (St. George's Hospital, UK) and Professor Gregory Lip (University of Birmingham Centre for Cardiovascular Sciences, UK) highlight the changes brought about by non-vitamin K antagonist oral anticoagulants (NOACs) in the field of stroke prevention in atrial fibrillation. Their discussions include how stroke prevention in atrial fibrillation has historically been managed, current treatment guidelines and the comparative efficacy and safety profiles of anticoagulant treatments.